<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20240704204225&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20240704204225&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 05 Jul 2024 00:42:26 +0000</lastbuilddate>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>TRIM35: A Proposed Gateway to p53-Induced Heart Failure Pathogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963873/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):314-316. doi: 10.1161/CIRCRESAHA.124.324792. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963873/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38963873</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324792>10.1161/CIRCRESAHA.124.324792</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963873</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Chang Jie Mick Lee</dc:creator>
<dc:creator>Roger S-Y Foo</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>TRIM35: A Proposed Gateway to p53-Induced Heart Failure Pathogenesis</dc:title>
<dc:identifier>pmid:38963873</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324792</dc:identifier>
</item>
<item>
<title>Combined Lipid Disturbances: More Than the Sum of Their Parts?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):277-279. doi: 10.1161/CIRCRESAHA.124.324793. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38963872</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324793>10.1161/CIRCRESAHA.124.324793</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963872</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert A Hegele</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Combined Lipid Disturbances: More Than the Sum of Their Parts?</dc:title>
<dc:identifier>pmid:38963872</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324793</dc:identifier>
</item>
<item>
<title>Breaking Point: How Intraplaque Hemorrhage Propels Plaque Rupture</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963871/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):317-319. doi: 10.1161/CIRCRESAHA.124.324795. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963871/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38963871</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324795>10.1161/CIRCRESAHA.124.324795</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963871</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Laura Parma</dc:creator>
<dc:creator>Johan Duchene</dc:creator>
<dc:creator>Christian Weber</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Breaking Point: How Intraplaque Hemorrhage Propels Plaque Rupture</dc:title>
<dc:identifier>pmid:38963871</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324795</dc:identifier>
</item>
<item>
<title>Phosphodiesterase Inhibitors in Cerebrovascular Perfusion and Pulsatility</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963870/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):332-334. doi: 10.1161/CIRCRESAHA.124.324954. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963870/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38963870</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324954>10.1161/CIRCRESAHA.124.324954</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963870</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jesus D Melgarejo</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Phosphodiesterase Inhibitors in Cerebrovascular Perfusion and Pulsatility</dc:title>
<dc:identifier>pmid:38963870</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324954</dc:identifier>
</item>
<item>
<title>"Tip" the Scale of Cardiac Repair via Reducing Pathological Extracellular Vesicles</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963869/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):298-300. doi: 10.1161/CIRCRESAHA.124.324955. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963869/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38963869</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324955>10.1161/CIRCRESAHA.124.324955</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963869</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhang Yue</dc:creator>
<dc:creator>Ke Cheng</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>"Tip" the Scale of Cardiac Repair via Reducing Pathological Extracellular Vesicles</dc:title>
<dc:identifier>pmid:38963869</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324955</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963868/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):262-264. doi: 10.1161/RES.0000000000000681. Epub 2024 Jul 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963868/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38963868</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000681>10.1161/RES.0000000000000681</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963868</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38963868</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000681</dc:identifier>
</item>
<item>
<title>Clinical Characteristics and Mechanisms of Acute Myocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963866/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>URL: https://www.clinicaltrials.gov; Unique identifier: NCT05335928.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):397-411. doi: 10.1161/CIRCRESAHA.124.324674. Epub 2024 Jul 4.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">URL: https://www.clinicaltrials.gov; Unique identifier: NCT05335928.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963866/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38963866</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324674>10.1161/CIRCRESAHA.124.324674</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963866</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephane Heymans</dc:creator>
<dc:creator>Sophie Van Linthout</dc:creator>
<dc:creator>Sarah Mignon Kraus</dc:creator>
<dc:creator>Leslie T Cooper</dc:creator>
<dc:creator>Ntobeko A B Ntusi</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Clinical Characteristics and Mechanisms of Acute Myocarditis</dc:title>
<dc:identifier>pmid:38963866</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324674</dc:identifier>
</item>
<item>
<title>Exploring the Function of Epicardial Cells Beyond the Surface</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963865/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>The epicardium, previously viewed as a passive outer layer around the heart, is now recognized as an essential component in development, regeneration, and repair. In this review, we explore the cellular and molecular makeup of the epicardium, highlighting its roles in heart regeneration and repair in zebrafish and salamanders, as well as its activation in young and adult postnatal mammals. We also examine the latest technologies used to study the function of epicardial cells for therapeutic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):353-371. doi: 10.1161/CIRCRESAHA.124.321567. Epub 2024 Jul 4.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The epicardium, previously viewed as a passive outer layer around the heart, is now recognized as an essential component in development, regeneration, and repair. In this review, we explore the cellular and molecular makeup of the epicardium, highlighting its roles in heart regeneration and repair in zebrafish and salamanders, as well as its activation in young and adult postnatal mammals. We also examine the latest technologies used to study the function of epicardial cells for therapeutic interventions. Analysis of highly regenerative animal models shows that the epicardium is essential in regulating cardiomyocyte proliferation, transient fibrosis, and neovascularization. However, despite the epicardium's unique cellular programs to resolve cardiac damage, it remains unclear how to replicate these processes in nonregenerative mammalian organisms. During myocardial infarction, epicardial cells secrete signaling factors that modulate fibrotic, vascular, and inflammatory remodeling, which differentially enhance or inhibit cardiac repair. Recent transcriptomic studies have validated the cellular and molecular heterogeneity of the epicardium across various species and developmental stages, shedding further light on its function under pathological conditions. These studies have also provided insights into the function of regulatory epicardial-derived signaling molecules in various diseases, which could lead to new therapies and advances in reparative cardiovascular medicine. Moreover, insights gained from investigating epicardial cell function have initiated the development of novel techniques, including using human pluripotent stem cells and cardiac organoids to model reparative processes within the cardiovascular system. This growing understanding of epicardial function holds the potential for developing innovative therapeutic strategies aimed at addressing developmental heart disorders, enhancing regenerative therapies, and mitigating cardiovascular disease progression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963865/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38963865</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.321567>10.1161/CIRCRESAHA.124.321567</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963865</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>David Wong</dc:creator>
<dc:creator>Julie Martinez</dc:creator>
<dc:creator>Pearl Quijada</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Exploring the Function of Epicardial Cells Beyond the Surface</dc:title>
<dc:identifier>pmid:38963865</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.321567</dc:identifier>
</item>
<item>
<title>Mitochondrial Structure and Function in Human Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38963864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>Despite clinical and scientific advancements, heart failure is the major cause of morbidity and mortality worldwide. Both mitochondrial dysfunction and inflammation contribute to the development and progression of heart failure. Although inflammation is crucial to reparative healing following acute cardiomyocyte injury, chronic inflammation damages the heart, impairs function, and decreases cardiac output. Mitochondria, which comprise one third of cardiomyocyte volume, may prove a potential...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 5;135(2):372-396. doi: 10.1161/CIRCRESAHA.124.323800. Epub 2024 Jul 4.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite clinical and scientific advancements, heart failure is the major cause of morbidity and mortality worldwide. Both mitochondrial dysfunction and inflammation contribute to the development and progression of heart failure. Although inflammation is crucial to reparative healing following acute cardiomyocyte injury, chronic inflammation damages the heart, impairs function, and decreases cardiac output. Mitochondria, which comprise one third of cardiomyocyte volume, may prove a potential therapeutic target for heart failure. Known primarily for energy production, mitochondria are also involved in other processes including calcium homeostasis and the regulation of cellular apoptosis. Mitochondrial function is closely related to morphology, which alters through mitochondrial dynamics, thus ensuring that the energy needs of the cell are met. However, in heart failure, changes in substrate use lead to mitochondrial dysfunction and impaired myocyte function. This review discusses mitochondrial and cristae dynamics, including the role of the mitochondria contact site and cristae organizing system complex in mitochondrial ultrastructure changes. Additionally, this review covers the role of mitochondria-endoplasmic reticulum contact sites, mitochondrial communication via nanotunnels, and altered metabolite production during heart failure. We highlight these often-neglected factors and promising clinical mitochondrial targets for heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38963864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38963864</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323800>10.1161/CIRCRESAHA.124.323800</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38963864</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Antentor Hinton</dc:creator>
<dc:creator>Steven M Claypool</dc:creator>
<dc:creator>Kit Neikirk</dc:creator>
<dc:creator>Nanami Senoo</dc:creator>
<dc:creator>Celestine N Wanjalla</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:creator>Clintoria R Williams</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Mitochondrial Structure and Function in Human Heart Failure</dc:title>
<dc:identifier>pmid:38963864</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323800</dc:identifier>
</item>
<item>
<title>Imaging of Existing and Newly Translated Proteins Elucidates Mechanisms of Sarcomere Turnover</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38962864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings establish a unidirectional replacement model for cardiac sarcomeres subunit replacement and identify their turnover principles.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 4. doi: 10.1161/CIRCRESAHA.123.323819. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: How the sarcomeric complex is continuously turned over in long-living cardiomyocytes is unclear. According to the prevailing model of sarcomere maintenance, sarcomeres are maintained by cytoplasmic soluble protein pools with free recycling between pools and sarcomeres.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We imaged and quantified the turnover of expressed and endogenous sarcomeric proteins, including the giant protein titin, in cardiomyocytes in culture and in vivo, at the single cell and at the single sarcomere level using pulse-chase labeling of Halo-tagged proteins with covalent ligands.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We disprove the prevailing protein pool model and instead show an ordered mechanism in which only newly translated proteins enter the sarcomeric complex while older ones are removed and degraded. We also show that degradation is independent of protein age and that proteolytic extraction is a rate-limiting step in the turnover. We show that replacement of sarcomeric proteins occurs at a similar rate within cells and across the heart and is slower in adult cells.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings establish a unidirectional replacement model for cardiac sarcomeres subunit replacement and identify their turnover principles.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38962864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38962864</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323819>10.1161/CIRCRESAHA.123.323819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38962864</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Guy Douvdevany</dc:creator>
<dc:creator>Itai Erlich</dc:creator>
<dc:creator>Lilac Haimovich-Caspi</dc:creator>
<dc:creator>Tomer Mashiah</dc:creator>
<dc:creator>Maksymilian Prondzynski</dc:creator>
<dc:creator>Maria Rosaria Pricolo</dc:creator>
<dc:creator>Jorge Alegre-Cebollada</dc:creator>
<dc:creator>Wolfgang A Linke</dc:creator>
<dc:creator>Lucie Carrier</dc:creator>
<dc:creator>Izhak Kehat</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Imaging of Existing and Newly Translated Proteins Elucidates Mechanisms of Sarcomere Turnover</dc:title>
<dc:identifier>pmid:38962864</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323819</dc:identifier>
</item>
<item>
<title>An Intramyocardial Mass Mimicking ST-Segment Elevation Myocardial Infarct at Presentation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>ST-segment elevation on the electrocardiogram typically indicates acute myocardial infarction but can mimic ST-segment elevation myocardial infarction in various conditions. We present a case of a patient with an intramyocardial mass and anterior ST-segment elevation without significant myocardial biomarker elevation. Multimodality imaging was crucial in revealing cardiac metastasis as the attributable cause.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):229-231. doi: 10.1016/j.jacc.2024.05.012.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">ST-segment elevation on the electrocardiogram typically indicates acute myocardial infarction but can mimic ST-segment elevation myocardial infarction in various conditions. We present a case of a patient with an intramyocardial mass and anterior ST-segment elevation without significant myocardial biomarker elevation. Multimodality imaging was crucial in revealing cardiac metastasis as the attributable cause.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38960518</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.012>10.1016/j.jacc.2024.05.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960518</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Mariana Ferreira Carvalho</dc:creator>
<dc:creator>Margarida Cabral</dc:creator>
<dc:creator>Carolina Gonçalves</dc:creator>
<dc:creator>Luís Graça Santos</dc:creator>
<dc:creator>João Morais</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>An Intramyocardial Mass Mimicking ST-Segment Elevation Myocardial Infarct at Presentation</dc:title>
<dc:identifier>pmid:38960518</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.012</dc:identifier>
</item>
<item>
<title>Insights From Midcareer Women in Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960517/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):219-222. doi: 10.1016/j.jacc.2024.04.049.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960517/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38960517</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.049>10.1016/j.jacc.2024.04.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960517</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Kamala P Tamirisa</dc:creator>
<dc:creator>Modele O Ogunniyi</dc:creator>
<dc:creator>Ming Hui Chen</dc:creator>
<dc:creator>Johanna Contreras</dc:creator>
<dc:creator>Ann T Tong</dc:creator>
<dc:creator>Madhavi Kadiyala</dc:creator>
<dc:creator>Jennifer A Tremmel</dc:creator>
<dc:creator>J Jane Cao</dc:creator>
<dc:creator>Nausheen Akhter</dc:creator>
<dc:creator>Sandra J Lewis</dc:creator>
<dc:creator>ACC’s Sandra J. Lewis Mid-Career Leadership Inaugural Cohort</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Insights From Midcareer Women in Cardiology</dc:title>
<dc:identifier>pmid:38960517</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.049</dc:identifier>
</item>
<item>
<title>Understanding JACC's Initial Submission Review: Rapid, Thorough, Fair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):216-218. doi: 10.1016/j.jacc.2024.05.035.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38960516</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.035>10.1016/j.jacc.2024.05.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960516</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Understanding JACC's Initial Submission Review: Rapid, Thorough, Fair</dc:title>
<dc:identifier>pmid:38960516</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.035</dc:identifier>
</item>
<item>
<title>Team-Driven Quality Improvement: The Key to Transforming Heart Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960515/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):213-215. doi: 10.1016/j.jacc.2024.05.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960515/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38960515</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.025>10.1016/j.jacc.2024.05.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960515</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Cathleen Biga</dc:creator>
<dc:creator>Andrea Price</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Team-Driven Quality Improvement: The Key to Transforming Heart Health</dc:title>
<dc:identifier>pmid:38960515</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.025</dc:identifier>
</item>
<item>
<title>Tricuspid Regurgitation in Patients With Heart Failure and Preserved Ejection Fraction: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>Heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and mortality. Important risk factors for the development of HFpEF are similar to risk factors for the progression of tricuspid regurgitation (TR), and both conditions frequently coexist and thus is a distinct phenotype or a marker for advanced HF. Many patients with severe, symptomatic atrial secondary TR have been enrolled in current transcatheter device trials, and may represent patients at an advanced...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):195-212. doi: 10.1016/j.jacc.2024.04.047.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and mortality. Important risk factors for the development of HFpEF are similar to risk factors for the progression of tricuspid regurgitation (TR), and both conditions frequently coexist and thus is a distinct phenotype or a marker for advanced HF. Many patients with severe, symptomatic atrial secondary TR have been enrolled in current transcatheter device trials, and may represent patients at an advanced stage of HFpEF. Management of HFpEF thus may affect the pathophysiology of TR, and the physiologic changes that occur following transcatheter treatment of TR, may also impact symptoms and outcomes in patients with HFpEF. This review discusses these issues and suggests possible management strategies for these patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38960514</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.047>10.1016/j.jacc.2024.04.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960514</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Frank Edelmann</dc:creator>
<dc:creator>Lars H Lund</dc:creator>
<dc:creator>Philip Lurz</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Ryan J Tedford</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tricuspid Regurgitation in Patients With Heart Failure and Preserved Ejection Fraction: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38960514</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.047</dc:identifier>
</item>
<item>
<title>Sex Differences, Graft Failure, and Mortality: An Ounce of Prevention After the Pound of Cure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):192-194. doi: 10.1016/j.jacc.2024.05.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38960513</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.008>10.1016/j.jacc.2024.05.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960513</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Amy A Sarma</dc:creator>
<dc:creator>Jared A Spitz</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sex Differences, Graft Failure, and Mortality: An Ounce of Prevention After the Pound of Cure</dc:title>
<dc:identifier>pmid:38960513</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.008</dc:identifier>
</item>
<item>
<title>Coronary Artery Bypass Graft Failure in Women: Incidence and Clinical Implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Graft failure is more frequent in women and is associated with adverse cardiac events. The excess mortality risk associated with female sex among CABG patients is not mediated by graft failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):182-191. doi: 10.1016/j.jacc.2024.04.046.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Women have worse outcomes after coronary artery bypass surgery (CABG) than men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to determine the incidence of CABG graft failure in women, its association with cardiac events, and whether it contributes to sex-related differences in outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A pooled analysis of individual patient data from randomized clinical trials with systematic imaging follow-up was performed. Multivariable logistic regression models were used to assess the association of graft failure with myocardial infarction and repeat revascularization between CABG and imaging (primary outcome) and death after imaging (secondary outcome). Mediation analysis was performed to evaluate the effect of graft failure on the association between female sex and risk of death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Seven randomized clinical trials (N = 4,413, 777 women) were included. At a median imaging follow-up of 1.03 years, graft failure was significantly more frequent among women than men (37.3% vs 32.9% at the patient-level and 20.5% vs 15.8% at the graft level; P = 0.02 and P &lt; 0.001, respectively). In women, graft failure was associated with an increased risk of myocardial infarction and repeat revascularization (OR: 3.94; 95% CI: 1.79-8.67) and death (OR: 3.18; 95% CI: 1.73-5.85). Female sex was independently associated with the risk of death (direct effect, HR: 1.84; 95% CI: 1.35-2.50) but the association was not mediated by graft failure (indirect effect, HR: 1.04; 95% CI: 0.86-1.26).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Graft failure is more frequent in women and is associated with adverse cardiac events. The excess mortality risk associated with female sex among CABG patients is not mediated by graft failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38960512</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.046>10.1016/j.jacc.2024.04.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960512</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Kevin R An</dc:creator>
<dc:creator>Lamia Harik</dc:creator>
<dc:creator>Rachel Heise</dc:creator>
<dc:creator>Antonino Di Franco</dc:creator>
<dc:creator>Stephen E Fremes</dc:creator>
<dc:creator>David L Hare</dc:creator>
<dc:creator>Alexander Kulik</dc:creator>
<dc:creator>Andre Lamy</dc:creator>
<dc:creator>Joyce Peper</dc:creator>
<dc:creator>Marc Ruel</dc:creator>
<dc:creator>Jurrien M Ten Berg</dc:creator>
<dc:creator>Laura M Willemsen</dc:creator>
<dc:creator>Qiang Zhao</dc:creator>
<dc:creator>Yunpeng Zhu</dc:creator>
<dc:creator>Daniel M Wojdyla</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Coronary Artery Bypass Graft Failure in Women: Incidence and Clinical Implications</dc:title>
<dc:identifier>pmid:38960512</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.046</dc:identifier>
</item>
<item>
<title>In Search of an Accurate Measurement of LDL-C: Correction for Lp(a)-Cholesterol to Predict Clinical Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960511/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):178-181. doi: 10.1016/j.jacc.2024.05.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960511/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38960511</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.009>10.1016/j.jacc.2024.05.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960511</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sotirios Tsimikas</dc:creator>
<dc:creator>Calvin Yeang</dc:creator>
<dc:creator>Florian Kronenberg</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>In Search of an Accurate Measurement of LDL-C: Correction for Lp(a)-Cholesterol to Predict Clinical Outcomes</dc:title>
<dc:identifier>pmid:38960511</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.009</dc:identifier>
</item>
<item>
<title>Impact of Lipoprotein(a) Level on Low-Density Lipoprotein Cholesterol- or Apolipoprotein B-Related Risk of Coronary Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Correction of LDL-C for its Lp(a)-C content provided no meaningful information on CHD-risk estimation at the population level. Simple categorization of Lp(a) mass (≥/&lt;90th percentile) influenced the association between LDL-C or apoB with future CHD mostly at higher Lp(a) levels.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):165-177. doi: 10.1016/j.jacc.2024.04.050.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Conventional low-density lipoprotein cholesterol (LDL-C) quantification includes cholesterol attributable to lipoprotein(a) (Lp(a)-C) due to their overlapping densities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purposes of this study were to compare the association between LDL-C and LDL-C corrected for Lp(a)-C (LDL<sub>Lp(a)corr</sub>) with incident coronary heart disease (CHD) in the general population and to investigate whether concomitant Lp(a) values influence the association of LDL-C or apolipoprotein B (apoB) with coronary events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among 68,748 CHD-free subjects at baseline LDL<sub>Lp(a)corr</sub> was calculated as "LDL-C-Lp(a)-C," where Lp(a)-C was 30% or 17.3% of total Lp(a) mass. Fine and Gray competing risk-adjusted models were applied for the association between the outcome incident CHD and: 1) LDL-C and LDL<sub>Lp(a)corr</sub> in the total sample; and 2) LDL-C and apoB after stratification by Lp(a) mass (≥/&lt;90th percentile).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Similar risk estimates for incident CHD were found for LDL-C and LDL-C<sub>Lp(a)corr30</sub> or LDL-C<sub>Lp(a)corr17.3</sub> (subdistribution HR with 95% CI) were 2.73 (95% CI: 2.34-3.20) vs 2.51 (95% CI: 2.15-2.93) vs 2.64 (95% CI: 2.26-3.10), respectively (top vs bottom fifth; fully adjusted models). Categorization by Lp(a) mass resulted in higher subdistribution HRs for uncorrected LDL-C and incident CHD at Lp(a) ≥90th percentile (4.38 [95% CI: 2.08-9.22]) vs 2.60 [95% CI: 2.21-3.07]) at Lp(a) &lt;90th percentile (top vs bottom fifth; P<sub>interaction</sub>0.39). In contrast, apoB risk estimates were lower in subjects with higher Lp(a) mass (2.43 [95% CI: 1.34-4.40]) than in Lp(a) &lt;90th percentile (3.34 [95% CI: 2.78-4.01]) (P<sub>interaction</sub>0.49).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Correction of LDL-C for its Lp(a)-C content provided no meaningful information on CHD-risk estimation at the population level. Simple categorization of Lp(a) mass (≥/&lt;90th percentile) influenced the association between LDL-C or apoB with future CHD mostly at higher Lp(a) levels.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38960510</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.050>10.1016/j.jacc.2024.04.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960510</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Natalie Arnold</dc:creator>
<dc:creator>Christopher Blaum</dc:creator>
<dc:creator>Alina Goßling</dc:creator>
<dc:creator>Fabian J Brunner</dc:creator>
<dc:creator>Benjamin Bay</dc:creator>
<dc:creator>Tanja Zeller</dc:creator>
<dc:creator>Marco M Ferrario</dc:creator>
<dc:creator>Paolo Brambilla</dc:creator>
<dc:creator>Giancarlo Cesana</dc:creator>
<dc:creator>Valerio Leoni</dc:creator>
<dc:creator>Luigi Palmieri</dc:creator>
<dc:creator>Chiara Donfrancesco</dc:creator>
<dc:creator>Francisco Ojeda</dc:creator>
<dc:creator>Allan Linneberg</dc:creator>
<dc:creator>Stefan Söderberg</dc:creator>
<dc:creator>Licia Iacoviello</dc:creator>
<dc:creator>Francesco Gianfagna</dc:creator>
<dc:creator>Simona Costanzo</dc:creator>
<dc:creator>Susana Sans</dc:creator>
<dc:creator>Giovanni Veronesi</dc:creator>
<dc:creator>Barbara Thorand</dc:creator>
<dc:creator>Annette Peters</dc:creator>
<dc:creator>Hugh Tunstall-Pedoe</dc:creator>
<dc:creator>Frank Kee</dc:creator>
<dc:creator>Veikko Salomaa</dc:creator>
<dc:creator>Renate B Schnabel</dc:creator>
<dc:creator>Kari Kuulasmaa</dc:creator>
<dc:creator>Stefan Blankenberg</dc:creator>
<dc:creator>Christoph Waldeyer</dc:creator>
<dc:creator>Wolfgang Koenig</dc:creator>
<dc:creator>BiomarCaRE Investigators</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Lipoprotein(a) Level on Low-Density Lipoprotein Cholesterol- or Apolipoprotein B-Related Risk of Coronary Heart Disease</dc:title>
<dc:identifier>pmid:38960510</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.050</dc:identifier>
</item>
<item>
<title>Bempedoic Acid Falls in Line</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):163-164. doi: 10.1016/j.jacc.2024.05.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38960509</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.027>10.1016/j.jacc.2024.05.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960509</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Maya S Safarova</dc:creator>
<dc:creator>Patrick M Moriarty</dc:creator>
<dc:creator>Iftikhar J Kullo</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Eugenia Gianos</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bempedoic Acid Falls in Line</dc:title>
<dc:identifier>pmid:38960509</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.027</dc:identifier>
</item>
<item>
<title>Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704204225&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Cardiovascular risk reduction with bempedoic acid is similar to that achieved with statins for a given absolute magnitude of LDL-C lowering. (Evaluation of Major Adverse Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated with Bempedoic Acid [ETC-1002] or Placebo [CLEAR Outcomes]; NCT02993406).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):152-162. doi: 10.1016/j.jacc.2024.04.048.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Outcomes trial, treatment of statin-intolerant patients with bempedoic acid produced a 21% decrease in low-density lipoprotein cholesterol (LDL-C) relative to placebo and a 13% relative reduction in the risk of major adverse cardiovascular events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine whether the relationship between LDL-C lowering and cardiovascular benefit achieved with bempedoic acid resembles that observed with statins when standardized per unit change in LDL-C.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To compare the treatment effect of bempedoic acid with statins, the methodology of the Cholesterol Treatment Trialists' Collaboration (CTTC) was applied to outcomes among the 13,970 patients enrolled in the CLEAR Outcomes trial. The CTTC endpoint of "major vascular event" was a composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal stroke, or coronary revascularization. HRs for CTTC-defined endpoints were normalized to 1 mmol/L differences in LDL-C levels between bempedoic acid and placebo groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A first major vascular event occurred in 703 (10.1%) patients in the bempedoic acid group and 816 (11.7%) patients in the placebo group (HR: 0.85; 95% CI: 0.77-0.94). When normalized per 1 mmol/L reduction in LDL-C, the HR was 0.75 (95% CI: 0.63-0.90), comparable to the rate ratio of 0.78 reported for statins in the CTTC meta-analysis. Normalized risk reductions were similar for bempedoic acid and statins for the endpoints of major coronary events, nonfatal myocardial infarction, and coronary revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Cardiovascular risk reduction with bempedoic acid is similar to that achieved with statins for a given absolute magnitude of LDL-C lowering. (Evaluation of Major Adverse Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated with Bempedoic Acid [ETC-1002] or Placebo [CLEAR Outcomes]; NCT02993406).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704204225&v=2.18.0.post9+e462414">38960508</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.048>10.1016/j.jacc.2024.04.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960508</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>A Michael Lincoff</dc:creator>
<dc:creator>Kausik K Ray</dc:creator>
<dc:creator>William J Sasiela</dc:creator>
<dc:creator>Tariq Haddad</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>Na Li</dc:creator>
<dc:creator>Leslie Cho</dc:creator>
<dc:creator>Denise Mason</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs</dc:title>
<dc:identifier>pmid:38960508</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.048</dc:identifier>
</item>





























</channel>
</rss>